- Home
- INFA vs BIO Comparison
INFA vs BIO Comparison
Compare INFA & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFA
- BIO
- Stock Information
- Founded
- INFA 1993
- BIO 1952
- Country
- INFA United States
- BIO United States
- Employees
- INFA N/A
- BIO N/A
- Industry
- INFA EDP Services
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- INFA Technology
- BIO Industrials
- Exchange
- INFA Nasdaq
- BIO Nasdaq
- Market Cap
- INFA 8.2B
- BIO 9.1B
- IPO Year
- INFA 2021
- BIO N/A
- Fundamental
- Price
- INFA $26.90
- BIO $327.15
- Analyst Decision
- INFA Buy
- BIO Strong Buy
- Analyst Count
- INFA 12
- BIO 4
- Target Price
- INFA $33.67
- BIO $414.00
- AVG Volume (30 Days)
- INFA 2.3M
- BIO 203.8K
- Earning Date
- INFA 02-12-2025
- BIO 02-13-2025
- Dividend Yield
- INFA N/A
- BIO N/A
- EPS Growth
- INFA N/A
- BIO N/A
- EPS
- INFA 0.21
- BIO N/A
- Revenue
- INFA $1,656,891,000.00
- BIO $2,580,209,000.00
- Revenue This Year
- INFA $6.70
- BIO N/A
- Revenue Next Year
- INFA $6.99
- BIO $2.92
- P/E Ratio
- INFA $126.22
- BIO N/A
- Revenue Growth
- INFA 6.98
- BIO N/A
- 52 Week Low
- INFA $22.08
- BIO $262.12
- 52 Week High
- INFA $39.80
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- INFA 53.67
- BIO 44.03
- Support Level
- INFA $25.84
- BIO $318.27
- Resistance Level
- INFA $27.34
- BIO $351.08
- Average True Range (ATR)
- INFA 0.96
- BIO 11.74
- MACD
- INFA -0.04
- BIO -0.86
- Stochastic Oscillator
- INFA 59.80
- BIO 27.06
About INFA Informatica Inc.
Informatica Inc is a pioneered new category of software, the Intelligent Data Management Cloud, or IDMC. IDMC is an AI-powered platform that connects, manages, and unifies data across any multi-cloud, hybrid system, empowering enterprises to modernize and advance data strategies.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.